Skip to main content
TipRanks
Go Ultimate75% OFF

Pacific Biosciences (P09) AI Stock Analysis

6 Followers
DE:P09

Pacific Biosciences

(XETRA:P09)

Rating:―N/A
Action:N/A
Date:―

No summary available

Positive Factors
Clinical GrowthClinical adoption is becoming a meaningful growth engine, with consumables revenue rising more than 20% year-over-year and testing moving toward commercialization. Greater clinical use can deepen recurring reagent demand, diversify customers beyond research markets, and support more durable platform utilization.
Negative Factors
Stressed Balance SheetNegative equity and substantial debt materially constrain financial flexibility while the company remains loss-making. This capital structure can limit investment choices, increase refinancing exposure, and make execution of product launches and commercial expansion more dependent on external financing.

Pacific Biosciences (P09) vs. iShares MSCI Germany ETF (EWG)

-50%-25%0%25%50%75%100%DE:P09+10.61%EWG+7.58%Dec '25Jan '26Feb '26Mar '26Apr '26May '26Jun '26Jul '26Aug '26Sep '26Oct '26Nov '26
Market Cap
EUR 568.27M
Dividend Yield
―
Average Volume (3M)
5,266
Price to Earnings (P/E)
-4.4
Beta (1Y)
0.09
Revenue Growth
-0.79%
EPS Growth
76.78%
Country
Germany
Employees
485
Sector
Healthcare
Sector Strength
51
Industry
Medical - Devices

Pacific Biosciences Business Overview & Revenue Model

Company Description

Pacific Biosciences of California, Inc. (PACB) specializes in pioneering and manufacturing advanced genetic sequencing platforms, empowering researchers and institutions to unravel intricate genetic challenges. At the heart of its offerings are the p...

Pacific Biosciences Earnings Call Summary

Earnings Call Date:Nov 04, 2026(Q3-2026)|% Change Since:-27.41%|Next Earnings Date:Feb 18, 2027
Earnings Call SentimentPositive

The call was broadly positive, with improving SPRQ-Nx adoption, clinical growth above 20% year-over-year, stronger instrument placements, strategic clinical and AI partnerships, and continued progress toward operating expense reduction and a 2028 cash flow breakeven target. These positives were tempered by lower year-over-year consumables revenue, a decline in gross margin, constrained academic and government funding, a reduced cash balance, and ongoing regional and capital-spending challenges.

Positive Updates

SPRQ-Nx Adoption Accelerated
More than half of Revio consumable revenue came from customers using SPRQ-Nx, and two-thirds of the Revio installed base had upgraded its software by quarter-end. PacBio expects the vast majority of the installed base to opt in by year-end.

Negative Updates

Consumables Revenue Remained Below Prior Year
Third-quarter consumables revenue was $20.8 million compared with $21.3 million in the third quarter of 2025. Year-over-year performance remained affected by customers working through existing reagent inventory and transitioning to multi-use workflows, with sequencing activity growing faster than consumable purchases.

Company Guidance

PacBio is narrowing full year revenue guidance to $155 million to $160 million, expects non-GAAP gross margin to be in the range of 35% to 37% for 2026, year-end cash of approximately $175 million to $185 million, and non-GAAP operating expenses in the range of $203 million to $207 million; it continues to expect full year consumables pull-through of $200,000 to $225,000 per Revio system, the vast majority of the installed base to opt in by year-end, cash burn to step down meaningfully in 2027, $15 million to $20 million in expected annual savings from reduced compensation-related expenses, an additional $15 million to $20 million in annual savings as development spending on the high throughput platform widens down, cash flow breakeven in 2028, a return back to that 225 to 250 pull-through range for consumables in 2027, and a commercial launch of the high throughput platform by the end of next year.

Pacific Biosciences Risk Analysis

Pacific Biosciences disclosed 66 risk factors in its most recent earnings report. Pacific Biosciences reported the most risks in the "Tech & Innovation" category.

Higher RiskSector Avg.Lower RiskFinance & CorporateTech & InnovationLegal & RegulatoryProductionAbility to SellMacro & Political
Tech & Innovation - Risks related to the company’s reliance on technology and ability to make innovative products

Latest Risks Added

1 New Risk
1.Our expense reduction initiatives could be disruptive to our operations and adversely affect our results of operations and financial condition, and we may not realize some or all of the anticipated benefits of these initiatives, whether in the time frame anticipated or at all.Q2, 2024

Pacific Biosciences Peers Comparison

Overall Rating

UnderperformOutperform
Sector (51)

Financial Indicators

DE:P09 against its peers
NameOverall RatingMarket CapP/E RatioROEDividend YieldRevenue GrowthEPS Growth
BIOBIO78Outperform$9.73B9.4114.07%―1.38%―
BRKRBRKR57Neutral$9.37B-55.94-5.15%0.33%2.16%-604.24%
CTKBCTKB53Neutral$745.47M-9.02-24.74%―5.50%-524.33%
Sector *51Neutral$7.86B-0.30-43.30%2.27%22.53%-2.21%
QSIQSI50Neutral$221.94M-2.57-44.72%―-60.18%40.20%
QTRXQTRX40Underperform$135.79M-1.21-42.99%―13.78%-1.29%

* Healthcare Sector Average

Performance Comparison

-50%0%50%DE:P09BIOBRKRQTRXQSICTKBDec '25Jan '26Feb '26Mar '26Apr '26May '26Jun '26Jul '26Aug '26Sep '26Oct '26Nov '26
DE:P09 and its peers over the selected period
Show on chartTickerCompany NamePriceChange% Change
DE:P09Pacific Biosciences1.650.2618.49%
BIOBio-Rad Laboratories358.1953.4017.52%
BRKRBruker Corporation61.3618.1542.02%
QTRXQuanterix2.86-3.00-51.19%
QSIQuantum-Si Incorporated1.01-0.27-21.09%
CTKBCytek Biosciences, Inc.5.700.448.37%
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.